Researchers from Bristol Myers Squibb Co. recently discussed the discovery and preclinical characterization of a series of Toll-like receptor 7 (TLR7) agonists with potential as anticancer drug candidates.
Synthesis and optimization of a series of 1H-pyrazolo[4,3d]pyrimidine molecules at Bristol Myers Squibb Co. led to the identification of compound [I] as the lead Toll-like receptor 7 (TLR7) agonist, with EC50 values of 21 and 94 nM for human and mouse TLR7, respectively.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified immunostimulatory antibody-drug conjugates (ISAC) comprising immunomodulators (Toll-like receptor 7 [TLR7] and/or TLR8 agonists) bound to antibodies through cleavable or uncleavable linkers reported to be useful for the treatment of cancer.
3M Innovative Properties Co. has synthesized immune response modifiers (IRMs) and their conjugates reported to be useful for the treatment of cancer and viral infections.
Shanghai Visonpharma Co. Ltd. has identified pyridine[4,3-d]pyrimidine compounds acting as Toll-Like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer and viral infection.
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
The State University of New York has presented new antibody-drug conjugates (ADCs) consisting of trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) covalently linked to Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer and infections.
Seagen Inc. and University of Minnesota have synthesized compounds and their antibody-drug conjugates (ADCs) comprising humanized monoclonal antibody (MAb) bound to Toll-like receptor 7 (TLR7) or TLR8 agonists through linker reported to be useful for the treatment of cancer.
